Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06415435 · ClinicalTrials.gov registry record · NA
Sylfirm X Radiofrequency Microneedling for the Treatment of Melasma
A NA study of Melasma, sponsored by Benev Company.
- Recruiting
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 3
- Study locations
NCT06415435 is a NA study of Melasma that is actively recruiting participants, run by Benev Company. The registered enrollment target is 90 participants, above the 34-participant average among 8 other Melasma trials with a reported enrollment target (165% higher). The trial reports 3 study locations across 3 states.
The verdict
NCT06415435, a NA study of Melasma, is actively recruiting participants, sponsored by Benev Company.
- RECRUITING
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 3
- Study locations
Study Summary
Microneedling radiofrequency technology has been shown in clinical studies to improve skin quality, tone, pigment, and to treat various skin conditions related to aging. The purpose of this study is to evaluate efficacy and safety of Sylfrim X device for the treatment of melasma.
Conditions Studied
Interventions
- DEVICE Radiofrequency Microneedling
Study Locations (3)
California
- Scripps Health - La Jolla
North Carolina
- Dermatology, Laser & Vein Specialists of the Carolinas, PLLC - Charlotte
Texas
- Refresh Dermatology - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2024-10-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06415435
The ClinicalTrials.gov registry entry for NCT06415435 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 34-participant average among 8 other Melasma trials with a reported enrollment target (165% higher). The listed sponsor is Benev Company, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melasma appearing as the primary indexed condition, and to 1 intervention - of which Radiofrequency Microneedling is the first listed.
NCT06415435 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT06415435 about?
NCT06415435 is a clinical study titled "Sylfirm X Radiofrequency Microneedling for the Treatment of Melasma". Microneedling radiofrequency technology has been shown in clinical studies to improve skin quality, tone, pigment, and to treat various skin conditions related to aging. The purpose of this study is to evaluate efficacy and safety of Sylfrim X device for the treatment of melasma.
What is the current status of trial NCT06415435?
This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2023-05-01. Estimated completion is 2024-10-01.
What conditions does trial NCT06415435 study?
This clinical trial studies the following conditions: Melasma.
What interventions are being tested in trial NCT06415435?
The interventions under investigation include: Radiofrequency Microneedling (DEVICE).
Who is sponsoring clinical trial NCT06415435?
This trial is sponsored by Benev Company, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06415435 being conducted?
This trial has 3 study locations across California, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melasma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
-
LaseMD System for the Treatment of Melasma
ACTIVE NOT RECRUITING · NA
-
Efficacy and Safety of PiQo4 Device for Treatment of Melasma
COMPLETED · NA
-
Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma
COMPLETED · NA
-
A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma
COMPLETED · NA
-
Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.